Abstract:e18524 Background: Chronic myeloid leukemia (CML) is a type of hematological malignancy characterized by the excessive proliferation of myeloid cells. Studies have shown that the presence of MF in CML patients has been associated with TFR. Identifying and assessing MF in CML patients at the time of diagnosis can provide valuable information for treatment planning and prognostic evaluation. Methods: The study enrolled 1757 CML-CP patients with pathological results of bone marrow biopsy. Patients with incomplete information from laboratory tests and medical records were excluded. The study was approved by the Ethics Committee of the First Affiliated Hospital of Zhejiang University School of Medicine and conducted in accordance with the Declaration of Helsinki. CML was diagnosed according to National Comprehensive Cancer Network (NCCN) 2023 version. Results: Patients with MF were found to be older (p<0.001) and had higher leukocyte (p<0.001) and platelet counts (p<0.001). They were also more likely to experience anemia (p<0.001), splenomegaly (p<0.001), patients with myelofibrosis had a higher percentage of eosinophils (p<0.001) and basophils (p<0.001) and had a higher proportion of peripheral blood blast cells (p<0.001) compared to patients without myelofibrosis. However, there was no significant difference in the male-to-female ratio between the two groups (p=0.690). Patients with MF were more unlikely to achieve certain treatment milestones, including a 3-month early molecular response (3M-EMR) (p<0.001), 6-month BCR-ABLIS ≤ 1% (p<0.001), and 12-month major molecular response (12M-MMR) (p<0.001). The proportion of medium/high-risk patients, as determined by Sokal score (p<0.001), Hasford score (p<0.001), ELTS score (p<0.001), and EUTOS score (p=0.002), was significantly increased in patients with MF (Table 1). Patients with MF had lower OS and PFS compared to patients without MF, indicating a potentially worse prognosis for those with MF. Patients with MF 10-year cumulative incidences of imatinib-therapy failure (p<0.001). However, there was no statistically significant difference in the treatment failure rate with different second-generation TKIs (p=0.222). CML-CP patients with MF who were treated with different TKIs were found that second-generation TKIs were more likely to achieve a 3-month EMR(p=0.009), 6-month BCR-ABLIS ≤ 1% (p=0.019), and 12-month MMR(p=0.015) compared to imatinib. Conclusions: Based on the available data, the results suggest that MF is indeed a poor prognostic factor for patients with CML. This finding highlights the importance of considering MF as a factor in assessing the outlook for CML patients. These findings indicate that second-generation TKIs are more effective in achieving molecular responses compared to imatinib, particularly in the context of myelofibrosis.

[Clinical Significance of Cytogenetic Monitoring in Chronic Myeloid Leukemia].

Cytogenetic profile of 1,863 Ph/BCR-ABL-positive chronic myelogenous leukemia patients from the Chinese population

Cytogenetic Analysis of 1863 Chineses Patients with Chronic Myeloid Leukemia

Characteristics and Outcome of Chromosomal Abnormalities in Ph Negative Cells of Chronic Myelogenous Leukemia Patients Treated with Tyrosine Kinase Inhibitors

[Cytogenetic and Molecular Analysis of 1193 Cases with Chronic Myeloid Leukemia].

Karyotypic Analysis and Prognosis for 41 Patients with Chronic Myelomonocytic Leukemia

The Treatment of Patients with Chronic Myeloid Leukemia Chronic Phase Combined with Myelofibrosis with Tyrosine Kinase Inhibitors: A Chinese Population-Based Study.

Detection of FLT3/ITD, JAK2(V617F) and NPM1 gene mutations in chronic myelomonocytic leukemia

Cytogenetic Alterations in CML: Not All Created Equal

Biological and Clinical Significance of Cytogenetic Study on 100 Acute Lymphoblastic Leukemia and 219 Acute Non-Lymphoblastic Leukemia.

Risk stratification of chromosomal abnormalities in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy.

Correlation between point mutation in ABL kinase and clinical outcome of chronic myeloid leukemia patients

Philadelphia Chromosome- Negative Myeloid Neoplasms in Patients with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia During Tyrosine Kinase Inhibtor-Therapy

Characterisation of Clonal Philadelphia-negative Cytogenetic Abnormalities in a Large Cohort of Chronic Myeloid Leukaemia

Cytogenetic analysis of 362 cases of chronic myeloid leukemia]

Correction: Chronic Myeloid Leukemia with Insertion-Derived BCR–ABL1 Fusion: Redefining Complex Chromosomal Abnormalities by Correlation of FISH and Karyotype Predicts Prognosis

Clinical Analysis of Cytogenetic Features in Acute Myeloid Leukemia and Its Relationship with Early Responses after Induction Therapy

Cytogenetic Analysis on 126 Cases of Acute Leukemia and Its Clinical Significance

Impact of Trisomy 8 on Treatment Response and Survival of Patients with Chronic Myelogenous Leukemia in the Era of Tyrosine Kinase Inhibitors.

Chromosomal Aberrations During Progression of Chronic Myeloid Leukemia Identified by Cytogenetic and Molecular Cytogenetic Tools: Implication of 1Q12-21.

[Comparative Study of Cytogenetic Response Evaluated by Conventional Banding Analysis and Fluorescence in Situ Hybridization in Chronic Myeloid Leukemia Patients During Tyrosine Kinase Inhibitor Treatment].